Systemic failure in metabolic liver disease diagnostics: How proteomic panels and global inequities reshape MASLD care pathways
Original framing: “[Articles] Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study” — The Lancet
Future modelling of MASLD diagnostics must account for three critical pathways: (1) *preventive stratification*, where AI-driven tools integrate proteomics with socioeconomic and environmental data to identify high-risk populations before fibrosis develops; (2) *culturally adaptive algorithms*, co-designed with Indigenous and traditional medicine practitioners to incorporate plant-based biomarkers and lifestyle factors; and (3) *regulatory sandboxes* for low-cost diagnostics in LMICs, leveraging telemedicine and community health workers. Scenario planning must also address the *feedback loops* between diagnostic innovation and corporate influence—e.g., how patented proteomic panels could become gatekeepers to care, as seen with hepatitis C treatments. Prior warnings from *systems biology* researchers highlight that MASLD’s complexity requires dynamic, not static, diagnostic models, yet the LITMUS study’s cross-sectional design fails to anticipate these future trajectories.
Text: The LITMUS study’s proteomic breakthrough in MASLD diagnostics obscures a deeper systemic failure: the medicalization of a condition whose true drivers are corporate lobbying, dietary industrialization, and healthcare inequities.
By centering high-tech panels without addressing their cost or cultural relevance, the narrative reinforces a Western biomedical hegemony that erases Indigenous knowledge (e.g., *Shipibo* plant medicines) and preventive frameworks (e.g., *Ayurvedic dinacharya*), which could provide scalable, low-cost solutions. Historical patterns—such as the 1990s HIV/AIDS crisis or the tobacco industry’s defeat—show that diagnostic innovation alone cannot fix epidemics rooted in structural power imbalances. The trickster irony here is that MASLD, a disease of excess, is now treated with *more* medical interventions, not systemic change. Solutions must integrate proteomics with socioeconomic data, co-design diagnostics with marginalised communities, and advocate for policies that target the root causes—ultra-processed food corporate influence and healthcare austerity—while restoring the cultural and historical precedents that once managed liver health holistically. The path forward lies not in scaling up the LITMUS model, but in dismantling the systems that created the epidemic in the first place.